Kamada (KMDA) Common Equity (2012 - 2026)
Kamada's (KMDA) quarterly Common Equity came in at $259.4 million in Q1 2026, up 2.95% YoY from $252.0 million in Q1 2025, and down 3.6% on a QoQ basis from $269.1 million in Q4 2025.
Kamada (KMDA) Common Equity (2012 - 2026) Analysis & Trends
Kamada (KMDA) has 15 years of Common Equity data on file, last reported at $259.4 million in Q1 2026.
- Quarterly Common Equity rose 2.95% year-over-year to $259.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259.4 million (up 2.95% YoY) and the FY2025 annual result came in at $269.1 million, up 3.7% from the prior year.
- Common Equity eased to $259.4 million in Q1 2026, from $269.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $269.1 million in Q4 2025 to a low of $171574.0 in Q2 2022.
- A 5-year average of $206.4 million and a median of $251.2 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 99.91% — and 2023, when it soared 138056.26%.
- Tracing KMDA's Common Equity over 5 years: stood at $176.0 million in 2022, then soared by 38.63% to $244.0 million in 2023, then climbed by 6.33% to $259.5 million in 2024, then grew by 3.7% to $269.1 million in 2025, then dropped by 3.6% to $259.4 million in 2026.
- The last three Common Equity figures came in at $259.4 million (Q1 2026), $269.1 million (Q4 2025), and $265.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Kamada | 465.78 Mn | 436.31 Mn | 22.47 Mn | 269.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 269.56 Mn |
| Mar 31, 2026 | 259.39 Mn |
| Dec 31, 2025 | 269.07 Mn |
| Sep 30, 2025 | 265.23 Mn |
| Jun 30, 2025 | 259.95 Mn |
| Mar 31, 2025 | 251.96 Mn |
| Dec 31, 2024 | 259.46 Mn |
| Sep 30, 2024 | 255.27 Mn |
| Jun 30, 2024 | 251.15 Mn |
| Mar 31, 2024 | 251.15 Mn |
| Dec 31, 2023 | 244.02 Mn |
| Sep 30, 2023 | 238.39 Mn |
| Jun 30, 2023 | 176.75 Mn |
| Mar 31, 2023 | 174.81 Mn |
| Dec 31, 2022 | 176.02 Mn |
| Sep 30, 2022 | 172,551.00 |
| Jun 30, 2022 | 171,574.00 |
| Mar 31, 2022 | 175.15 Mn |
| Dec 31, 2021 | 176.82 Mn |
| Sep 30, 2021 | 181.61 Mn |